Special Focus Review
Recombinant allergens: The present and the future
Volume 8, Issue 10
Purchase or Subscribe
Pages 1534 - 1543http://dx.doi.org/10.4161/hv.22064
: allergen-specific immunotherapy, allergy, hypoallergens, recombinant allergens, vaccines
Authors: Marek Jutel, Katarzyna Solarewicz-Madejek and Sylwia Smolinska View affiliations
Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.
Received: June 28, 2012; Accepted: September 3, 2012; Published Online: October 1, 2012
Full Text - Ahead of Print Available - Log in!